dymista 137 mikrog/ dose / 50 mikrog/ dose
viatris as - azelastinhydroklorid / flutikasonpropionat - nesespray, suspensjon - 137 mikrog/ dose / 50 mikrog/ dose
lamictal 200 mg
glaxosmithkline as - lamotrigin - tyggetablett/dispergerbar tablett - 200 mg
lamictal 2 mg
glaxosmithkline as - lamotrigin - tyggetablett/dispergerbar tablett - 2 mg
lamictal 5 mg
glaxosmithkline as - lamotrigin - tyggetablett/dispergerbar tablett - 5 mg
lamictal 25 mg
glaxosmithkline as - lamotrigin - tyggetablett/dispergerbar tablett - 25 mg
lamictal 50 mg
glaxosmithkline as - lamotrigin - tyggetablett/dispergerbar tablett - 50 mg
lamictal 100 mg
glaxosmithkline as - lamotrigin - tyggetablett/dispergerbar tablett - 100 mg
dymista 137 mikrog/ dose / 50 mikrog/ dose
paranova as - azelastinhydroklorid / flutikasonpropionat - nesespray, suspensjon - 137 mikrog/ dose / 50 mikrog/ dose
dymista 137 mikrog/ dose / 50 mikrog/ dose
orifarm as - azelastinhydroklorid / flutikasonpropionat - nesespray, suspensjon - 137 mikrog/ dose / 50 mikrog/ dose
opfolda
amicus therapeutics europe limited - miglustat - glykogen storage sykdom type ii - andre fordøyelseskanaler og metabolisme produkter - opfolda (miglustat) is an enzyme stabiliser of cipaglucosidase alfa long-term enzyme replacement therapy in adults with late-onset pompe disease (acid α- glucosidase [gaa] deficiency).